Phase 3 Stroke Trial, Recruiting NCT06768138 Sponsor: Central Hospital, Nancy, France Condition: Stroke
Back to Stroke

Phase 3 Stroke Trial, Recruiting

NCT06768138
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older
  • People who had little to no disability before their stroke (able to carry out usual activities with at most minor symptoms)
  • People who have had an acute ischemic stroke (caused by a blockage) in a specific group of large blood vessels at the front of the brain, confirmed by a CT or MRI scan
  • People whose stroke symptoms were measured as moderately severe or worse on a standard stroke scale at the time of hospital admission
  • People who received a treatment to restore blood flow to the brain within 24 hours of the stroke starting, in line with international medical guidelines
  • People whose brain scan results show that only a limited area of the brain has been severely damaged (specific scan score thresholds apply — confirm with trial site)
  • For patients transferred from another hospital, the time between the brain scan and the start of the procedure must be within 3 hours
  • People in whom blood flow to the brain was successfully restored (to a defined level) after treatment, confirmed by a specialised imaging procedure called a catheter angiogram
  • People who are enrolled in or covered by a French social security plan

Who may not be able to join:

  • People who do not speak French
  • People who have certain medical conditions that make a specific type of clot-dissolving treatment (intra-arterial thrombolysis) unsafe, including very low platelet counts, certain blood-thinning medication use within 48 hours, or other blood clotting concerns (confirm with trial site for specific details)
  • People who experienced complications during their stroke procedure that increase the risk of bleeding, such as a tear in the carotid artery or difficulties with the access point used for the procedure
  • People who had a fall during their stroke that raises the risk of bleeding complications
  • People whose stroke procedure required more than 5 thrombectomy devices (tools used to remove the clot)
  • People who have bleeding inside the brain
  • People who required a stent (a small tube to hold a blood vessel open) to treat a blockage or severe narrowing
  • People who are not expected to be available or able to attend a follow-up visit at 3 months
  • People who are currently participating in, or have participated in within the past 30 days, another clinical trial that may affect their recovery outcomes
  • Women of childbearing age who are not using effective contraception
  • People who fall under specific protected categories defined by the French Public Health Code (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +33 3 83 85 15 01

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
1 June 2025
Est. completion
16 September 2028

Where this trial is recruiting

🇫🇷 France

Primary endpoints

The superiority of adjunct intra-arterial thrombolysis versus no adjunct intra-arterial thrombolysis

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov